KYBORA’s Key Takeaways from JPM 2026
- Sentiment is improving: optimism is back across the room, with innovation tailwinds from new modalities opening fresh avenues for discovery.
- M&A is poised to accelerate: few headline deals landed during the conference, but the chatter points to an active 2026 driven by quality, differentiated assets. Oncology dominates – roughly a third of deal activity – with acquirers chasing precision-led assets to offset patent cliffs.
- The financing window is reopening: anticipated rate cuts and a public-market rebound are reviving IPOs (Aktis Oncology’s $318M debut, plus expected names like Kardigan, Parabilis, Apotex, Keenova). Private credit is open, defined by defensive stability and M&A-driven demand.
- AI is reshaping the value chain: seen as a productivity driver across discovery, disease modeling, and trials – already validated by Insilico’s Rentosertib, where both target and compound were AI-discovered.
- Therapeutic focus is shifting to scale: obesity, CV/metabolic, and CNS stay central; Eli Lilly’s valuation shows what “winning at scale” looks like. PE interest in development-stage opportunities is rising.
- China discovery is taking center stage: big pharma BD leaders are impressed by the quality and quantity of Chinese assets – an unprecedented partnering opportunity, and a growing threat-or-opportunity for US and European biotech.
- US price-control risk is real: healthcare costs will be a major election topic. Expect continued pressure on PBMs and insurers, rising direct-to-patient interest, and MFN risk already cooling cross-border licensing.
- Rare disease is consolidating: big pharma is moving toward larger markets with ~$2B+ peak-sales thresholds, opening M&A room for mid-cap biotechs.
- Japan and China commercialization is back in focus: Japan’s regulatory changes on drug loss and China’s private-insurance growth are improving the commercial outlook.
- ROW competition is heating up: players like Sobi, Arcera, Swixx, and BeOne are positioning as partners of choice across licensing, distribution, acquisitions, and named-patient programs – with MFN concerns creating openings to acquire ex-US rights.
- The US trial landscape is saturated and expensive: expect more sites to move offshore, with Brazil and Australia benefiting disproportionately.
